Scarica l'app Stockscreener
4.64
1.49%
-0.07
Alvotech Borsa (ALVO) Ultime notizie
Can Alvotech be recession proofJuly 2025 EndofMonth & Weekly Watchlist for Consistent Profits - mfd.ru
Can Alvotech Equity Warrant maintain its current growth rateMarket Growth Summary & Verified Swing Trading Watchlist - mfd.ru
Is Alvotech the Next Big Biotech Rocket or Just Hype? Real Talk on This Viral Underdog Stock - AD HOC NEWS
Alvotech’s AVT03 Biosimilar Gains European Approval - MSN
How Alvotech (ALVO) Affects Rotational Strategy Timing - Stock Traders Daily
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar - MSN
Assessing Alvotech (ALVO) Valuation After AVT80 Trial Success And New Sandoz Agreements - simplywall.st
Alvotech Increases Share Capital by $125,000 Through Issuance of 12.5 Million Ordinary Shares - Quiver Quantitative
Biotech Alvotech issues 12.5M shares, outstanding count unchanged - Stock Titan
Alvotech (ALVO) Investor Outlook: Exploring a 331% Potential Upside in the Biosimilars Market - DirectorsTalk Interviews
ALVO Investor News: If You Have Suffered Losses in Alvotech - GlobeNewswire
ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech - GlobeNewswire
Press releases provided by CNW - Techaeris
Aug Drivers: What is the Moat Score of Alvotech Equity WarrantQuarterly Trade Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Alvotech Faces Securities Claims Investigation - Intellectia AI
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - morningstar.com
Alvotech Enters Supply and Commercialization Agreements for Canada and Australia & New Zealand Covering Multiple Biosimilar Candidates - 富途牛牛
Are Expanded Sandoz Biosimilar Deals Quietly Reframing Alvotech’s Partnership Strategy and Scale Ambitions (ALVO)? - simplywall.st
Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio - MSN
Positive PK Results Put Alvotech’s Vedolizumab Biosimilar On Path Toward Filings - Citeline News & Insights
Private Equity Firms Are Alvotech's (NASDAQ:ALVO) Biggest Owners and Were Hit After Market Cap Dropped US$63m - 富途牛牛
Alvotech Hits Pivotal Milestone With Positive PK Data for Entyvio Biosimilar AVT80 - TipRanks
Alvotech (NASDAQ: ALVO) posts positive pivotal data for Entyvio biosimilar - Stock Titan
Alvotech Reports Positive Top-line Pharmacokinetic Study Results For AVT80, A Biosimilar To Entyvio - Nasdaq
Why Is ALVO Stock Rising Pre-Market Today? - Stocktwits
Alvotech (NASDAQ:ALVO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Alvotech Reports Positive Results for AVT80 Clinical Study - Intellectia AI
Fuji Pharma Lifts Sales Outlook but Slashes Profit Forecast on Alvotech Valuation Loss - TipRanks
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® - The Manila Times
Alvotech Announces Positive Top-Line Results from AVT80 Pharmacokinetic Study Compared to Entyvio® - Quiver Quantitative
Alvotech (ALVO): A Bull Case Theory - Finviz
ROSEN, A LEADING NATIONAL FIRM, Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - marketscreener.com
Alvotech (ALVO): A bull case theory - MSN
Alvotech (ALVO) Growth Potential: A Deep Dive into Its 316.67% Upside and Biosimilar Innovations - DirectorsTalk Interviews
Is It Time To Reconsider Alvotech (ALVO) After Its Sharp Three-Year Share Price Slide? - simplywall.st
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - TMX Newsfile
Assessing Alvotech (ALVO) Valuation After Mixed Short Term Gains And A Steep One Year Decline - Yahoo Finance
Alvotech appoints Lisa Graver as CEO - Pharmafile
Chipmakers Recap: How does Alvotech score in quality rankingsMarket Performance Summary & Free Verified High Yield Trade Plans - baoquankhu1.vn
Alvotech (NASDAQ:ALVO) Trading Down 0.9%Should You Sell? - MarketBeat
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged ... - Bluefield Daily Telegraph
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates - wahanariau.com
Alvotech’s Volatile Climb: Can A High?Beta Biosimilar Pure?Play Win Back Investor Trust? - AD HOC NEWS
Death Cross: Is Alvotech stock overvalued or fairly pricedMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Alvotech Hooks Up With Sandoz For Biosimilars In Canada, Australia And New Zealand - Citeline News & Insights
Alvotech Strikes Sandoz Biosimilar Supply and Commercialization Deals in Canada, Australia and New Zealand - TipRanks
Alvotech (NASDAQ: ALVO) inks Sandoz biosimilar pacts for Canada, Australia and New Zealand - Stock Titan
Alvotech Signs Biosimilar Supply, Commercialization Deals with Switzerland's Sandoz - marketscreener.com
Alvotech Enters Supply, Commercialization Deal With Sandoz Covering Biosimilar Candidates - Nasdaq
Alvotech Enters Supply Agreements with Sandoz for Biosimilars - intellectia.ai
Alvotech Secures Supply and Commercialization Agreements with Sandoz for Biosimilars in Canada, Australia, and New Zealand - Quiver Quantitative
Bond Watch: What is the Moat Score of Alvotech Equity Warrant2025 Trading Volume Trends & Weekly Sector Rotation Insights - baoquankhu1.vn
Aug Levels: Is Alvotech stock showing strong momentum2025 Performance Recap & Low Drawdown Momentum Ideas - baoquankhu1.vn
How Investors May Respond To Alvotech (ALVO) Securing Global Rights For Its Eylea Biosimilar Launch - Sahm
(ALVO) and the Role of Price-Sensitive Allocations - Stock Traders Daily
GAUZ IMPORTANT DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Gauzy Ltd. Investors to Secure Counsel Before Important February 6 Deadline in Securities Class Action - GlobeNewswire Inc.
1.19%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):